Qualitative and quantitative characterization of antibodies and proteins by CE-MS, LC-MS and an automated immunoaffinity purification (IA)- CE-MS workflow in vitro and in vivo
10 Dec 2019

Protein therapeutics of increasing complexity are playing a growing role in the pharmaceutical market. As a result, understanding the absorption, distribution, metabolism and excretion (ADME) of proteins has become more important to enable engineering strategies designed to optimize therapeutic properties of candidate molecules. To this end it is important to have robust methods, such as mass spectrometry, to characterize potential instability across a variety of sample types.

Intact mass spectrometry of therapeutic proteins offers the highest possible resolution to assess protein/peptide integrity as well as post-translational modifications. Despite the benefits of intact protein mass spectrometry, analysis from serum remains challenging. Enrichment or purification is required prior to mass spectrometry analysis of therapeutic proteins in serum due to high abundance of endogenous serum proteins. This webinar will describe the qualitative and quantitative characterization of mAb and protein stability, both in vitro and in vivo, by CE-MS and LC-MS.

Who Should Attend

  • Drug discovery, development and QA/QC scientists who are doing protein characterization
  • Application chemists
  • Biopharma scientists
  • Process chemists
  • Anyone with an interest in biotherapeutic development


For Research Use Only. Not for use in diagnostic procedures.

Agilent Technologies